Therapeutics

Bacteria
#Drug development #Drug discovery #Events #Microbiome #Therapeutics

Take aways from Microba’s presentation at European summit

Microba Life Sciences, a precision microbiome science company based in Australia, showcased its therapeutic platform and discovery platform for the identification of novel microbial signatures at Microbiome Movement, a European drug development summit, on January 27.  The event  The event brought together researchers from the biopharmaceutical… Read More

#News

#Biopharmaceuticals #Drug discovery #R&D #Therapeutics

Sitting down with… Dr Michael Hayden, Prilenia Therapeutics

Listen to this article on the DDW Podcast: Dr Michael Hayden's early encounters and experience with patients and families suffering from Huntington’s Disease has had a significant personal impact that shaped his career. As CEO of Prilenia Therapeutics, he tells Lu Rahman why he has dedicated his career to advancing research… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Acquisition #Collaboration #Oncology #T-Cells #Therapeutics

Takeover plan looks to develop T cell engager therapies 

Tokyo-based Takeda Pharmaceutical has optioned to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.   The acquisition   Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programmes. Adaptate’s γδ T cell engagers are… Read More

#News

#Biology #Drug discovery #Protein chemistry / Proteomics #Therapeutics

Why the emergence of targeted protein degradation is so exciting 

Listen to this article on the DDW Podcast: Last year a new translational research centre was established to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) would allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has… Read More

#hidden

#Biotechnology #Life sciences #Therapeutics

PhoreMost expands into new facility  

PhoreMost it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, designed to support PhoreMost’s phenotypic screening requirements and expertise. The new facility enables the company to add in-house flow cytometry and imaging capabilities.  Dr Chris Torrance, CEO of PhoreMost, said: “Our move to Unity Campus follows… Read More

#News

#Biotechnology #Drug discovery #Therapeutics

Drug discovery movers: who’s going where? 

The new year is underway and with it comes a raft of movement within some of the industry’s key businesses. DDW’s Megan Thomas rounds up seven new additions to the sector.  Dr Charles Woler (Sygnature Discovery, UK)  Sygnature Discovery, provider of drug discovery solutions, has appointed Dr Charles Woler as Chairman. Dr Woler has… Read More

#News #Trending News

#Antibodies #Autoimmune disease #Clinical trials #Therapeutics

eBook: Antibody production

In immunoassays-based research, immunodiagnostics, as well as immunotherapy, one of the highly critical aspect of antibodies is their reproducible performance. Antibody reproducibility is driven by their specificity and several other factors ranging from antibody design to target validation. This NEW eBook Antibody Production gives you an overview of the… Read More

#News

Patient receiving eye drops
#Clinical trials #Eye health #Healthcare #Therapeutics

Stuart Therapeutics Phase II clinical trial results of its dry eye candidate  

Stuart Therapeutics, a clinical stage, ophthalmic therapeutic development company, has announced the topline results of the first in human Phase II clinical trial for its lead drug candidate, ST-100 in patients with dry eye disease.   The trial  The clinical trial, conducted between June and October… Read More

#News

#CRISPR #Drug discovery #Precision medicine #Therapeutics

Therapeutics: Changing the way we treat disease – podcast 

The latest free-to-listen DDW podcast episode is titled “Therapeutics: Changing the way we treat disease”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “Avoiding double strand breaks on… Read More

#News

#Biotechnology #Clinical trials #Drug design #Drug development #Rare disease #Therapeutics

Inside the rare disease centre which aims to accelerate biotech growth 

Emmes has launched a rare disease centre, Orphan Reach, to combine its health research across the public sector and biopharmaceutical industry. DDW’s Megan Thomas spoke with Thomas Ogorka, Managing Director of Orphan Reach: Emmes’ Rare Disease Center, about its potential.  MT: What will the expanded Orphan Reach centre add to what Emmes already offers?   TO: First and foremost, specialised rare… Read More

#Exclusive Content #News #Opinion

#Antibodies #Covid-19 #Nanobodies #Therapeutics

Can llama antibodies help develop a Covid-19 therapy?

Amid the growing threat of a new and potentially more dangerous SARS-CoV-2 variant, scientists are ramping up the quest for Covid treatments. A recent study demonstrates the therapeutic potential of an unusual class of immune proteins: miniature antibodies called nanobodies, derived from llamas. Rockefeller University scientists Michael P. Rout and Brian T. Chait and… Read More

#Covid-19 #Editor's Choice #News

#Biotechnology #Clinical trials #Immunotherapy #Therapeutics #Tumours

Biotheus’ bifunctional therapeutic FDA-approved to enter Phase II studies 

Biotheus, a biotechnology company based in Zhuhai, China, with multiple clinical-stage assets under clinical development, has announced that its anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the United States Food and Drug Administration (FDA) for conducting clinical Phase II studies as part of an international multicentre clinical trial. … Read More

#News

MicroRNA
#Biopharmaceutical #Drug development #Pharmaceuticals #Therapeutics

Regulus appoints VP of chemistry and pharmaceutical development 

Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs, has appointed Mohammad Ahmadian as Vice President of Chemistry and Pharmaceutical Development.   The role  In his role, Dr. Ahmadian will assist in managing research and development of the company’s drug… Read More

#News

#Antibodies #Biotechnology #Cancer research #Immunotherapy #Therapeutics

MImAbs acquires antibody discovery system

MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to help its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases.  The acquisition  This marks the first Beacon platform to be used in France, which enables MImAbs to provide research institutions,… Read More

#News

#Biosciences #Drug development #Funding #RNA #Technology #Therapeutics

Sixfold Bioscience completes $10.5 million seed financing 

Sixfold Bioscience (Sixfold), a company using computation and advanced chemistry to design RNA therapeutic delivery systems, has raised $10.5 million in its seed funding round, which will support the continued development of the company’s Mergo RNA therapeutics delivery platform.  Investors   Investors in the seed round included Cantos Ventures, Y Combinator, Lombard Street… Read More

#Business & Investment #News